| Page 33 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study

Author(s): 
Chen M, Liu Q, Gao Y, Suo X, Ding X, Wang L, Li L, Shao Y, Gao D, Sun W, Tan Y, Wang W, Ye F, Han B
Primary Author: 
Chen M
Journal Title: 
European Journal of Haematology
Original Publication Date: 
Jun 2023

Aims: To compare cyclosporine (CSA) combining eltrombopag (EPAG) with or without antithymocyte globulin (ATG) in

Bone Marrow Disease(s): 

IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Author(s): 
Gurnari C, Prata PH, Catto LFB, Durmaz A, Larcher L, Sebert M, Allain V, Kewan T, Pagliuca S, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Socié G
Primary Author: 
Gurnari C
Journal Title: 
Blood
Original Publication Date: 
Jun 2023
Bone Marrow Disease(s): 

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

Author(s): 
Abel GA, Hebert D, Lee C, Rollison DE, Gillis N, Komrokji RS, Foran JM, Liu JJ, Al Baghdadi T, Deeg HJ, Gore SD, Saber W, Wilson SH, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA
Primary Author: 
Abel GA
Journal Title: 
Blood Advances
Original Publication Date: 
May 2023

Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with

Bone Marrow Disease(s):